During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
News|Articles|September 4, 2026
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
Author(s)Ashling Wahner
Fact checked by: Riley Kandel
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Advertisement
Advertisement
A wave of minimally invasive surgical methods and implantable radiation technology is revolutionizing brain cancer care, with experts emphasizing that these modalities complement, rather than replace, traditional methods and require multidisciplinary, patient-specific decision-making.
Related to this article
The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.
The ASPEN-09-03 trial is evaluating evorpacept plus trastuzumab and chemotherapy in previously treated HER2-positive metastatic breast cancer.
The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
Advertisement
Advertisement